News and Trends 26 Jun 2018 Update: The FDA Approves First Cannabinoid Treatment for Epilepsy Update (26/06/2018): The FDA has approved GW Pharmaceutical’s drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach the market. Published on 20/04/2018 GW Pharmaceuticals has received a unanimous recommendation from the FDA Advisory Committee Meeting supporting the approval of what could soon […] June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 A Biodegradable Plaster Could Help us Treat Mouth Ulcers British researchers and a Danish biotech have joined forces to develop a polymer patch that can treat mouth ulcer patients with long-term steroid release and make the wound-healing process faster. Dermtreat, based in Copenhagen, and researchers from the University of Sheffield’s School of Clinical Dentistry in the UK made a patch from polymers that stick […] June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Cambridge Biotech Raises €32M Series A Round to Treat Chronic Inflammation NodThera raised £28M (€32M) in a Series A round co-led by Sofinnova Partners and 5AM Ventures to develop treatments for chronic inflammation. NodThera, based in Cambridge, UK, closed a substantial Series A financing round to develop its lead small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and […] June 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic Alzheimer’s drug. The company plans to enroll a total of 90 patients in Spain, France and the UK. Update (14/05/2018): Oryzon has been given approval to expand to France its Phase IIa clinical trial for an epigenetic Alzheimer’s drug. The […] June 25, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III Results A nanomedicine designed to help amplify and focus radiation treatment on hard to treat soft tissue sarcoma cells has achieved positive Phase II/III trial results for French-American biotech Nanobiotix. “Data are exceptional and show without any doubt an improvement of radiation therapy impact,” commented Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at […] June 22, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2018 Next-Generation CAR-T Company Raises €130M on NASDAQ IPO London-based Autolus has made its debut on the NASDAQ raising funds to boost the development of a next generation of CAR-T cell therapy for cancer. Founded in 2014 as a spin-out from University College London, Autolus has been taking great strides to develop its CAR-T technology. In less than four years, the company managed to raise nearly €150M […] June 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2018 Gene Editing Could Cut the Cost of One of the Most Expensive Animal Diseases in the World Researchers at the University of Edinburgh have genetically engineered pigs that are resistant to a common disease that has exorbitant costs to the livestock industry. Researchers at the University of Edinburgh, in collaboration with the animal genetics company Genus, have produced pigs that are resistant to one of the most costly animal diseases in the […] June 21, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2018 Massive Series B Funding Could Bring Belgian Immuno-oncology Treatments Into the Clinic iTeos Therapeutics raised €65M ($75M) to bring two of its cancer treatments into the clinic within the next one and a half years. iTeos Therapeutics, a Belgian biotech, raised what may have been the largest Series B financing round in Europe so far this year, led by MPM Capital. The funding will be used to […] June 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2018 Gates Foundation and Oxitec Fight Malaria with Genetically-Modified Mosquitoes The Bill & Melinda Gates Foundation has partnered with Oxitec for the development of a new strain of genetically-modified mosquitoes that can help reduce the spread of malaria in America. In its latest effort to free the world of malaria, the Bill & Melinda Gates Foundation has joined forces with Oxitec, a British company that […] June 20, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2018 A Chip Could Help Us Identify Wheeze-Causing Types of Viruses Researchers in Vienna have developed a chip that identifies cold viruses that cause flare-ups of respiratory conditions such as asthma. The technology could help identify culprit viruses and help those affected take the best preventive and treatment measures. The chip, created by researchers at the Medical University of Vienna, uses a small blood sample to […] June 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2018 Biomaterial to Regenerate Teeth Approved in Europe The Israeli company Datum Dental has received approval to launch a biomaterial for dental implants in Europe and Canada. Datum Dental has developed a biomaterial specifically designed to help the body regenerate real bone tissue after dental operations. Launched in the US last year, the biomaterial has now received CE marking in Europe and approval […] June 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2018 London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […] June 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email